![]() |
![]() |
Legal status
Patent not validated
(51) | INT.CL. | C07D 409/10 | |
A61K 31/381 | |||
A61P 3/10 |
(11) | Number of the document | 3298007 |
(13) | Kind of document | T |
(96) | European patent application number | 16730933.5 |
Date of filing the European patent application | 2016-05-18 | |
(97) | Date of publication of the European application | 2018-03-28 |
(45) | Date of publication and mention of the grant of the patent | 2020-07-22 |
(46) | Date of publication of the claims translation |
(86) | Number | PCT/US2016/033071 |
Date | 2016-05-18 |
(87) | Number | WO 2016/191173 |
Date | 2016-12-01 |
(30) | Number | Date | Country code |
201562165265 P | 2015-05-22 | US |
(72) |
BRESLIN, David T., US
FAWZY, Nagy E., US
SCHAEFER, John, US
|
(73) |
Janssen Pharmaceutica NV,
Turnhoutseweg 30, 2340 Beerse,
BE
|
(54) | ANHYDROUS CRYSTALLINE FORM OF (1S)-1,5-ANHYDRO-1-[3-[[5-(4-FLUOROPHENYL)-2-THIENYL]METHYL]-4-METHYLPHENYL]-D-GLUCITOL |
ANHYDROUS CRYSTALLINE FORM OF (1S)-1,5-ANHYDRO-1-[3-[[5-(4-FLUOROPHENYL)-2-THIENYL]METHYL]-4-METHYLPHENYL]-D-GLUCITOL |